COVID-19 drug prospects boosted by discovery of short form of coronavirus's 'entry point'

A shadow over the promising inhaled interferon beta COVID-19 therapy has been cleared with the discovery that although it appears to increase levels of ACE2 protein -- coronavirus' key entry point into nose and lung cells -- it predominantly increases levels of a short version of that protein, which the virus cannot bind to.

from Top Health News -- ScienceDaily https://ift.tt/2MXsi0j